

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

StarGlory Holdings Company Limited **榮暉控股有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8213)

VOLUNTARY ANNOUNCEMENT **BUSINESS UPDATE**

This announcement is made by StarGlory Holdings Company Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

Reference is made to the announcements of the Company dated 19 February 2020, 5 March 2020 and 13 July 2020 in relation to incorporation of a new subsidiary to commence new business and entering into an operational service agreement in relation to, amongst others, provision of the management services by StarGlory Enterprise Management (Shenzhen) Company Limited* (榮暉企業管理(深圳)有限公司) (“**StarGlory Shenzhen**”), which is an indirect wholly-owned subsidiary of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, as advised by Huayin (Shenzhen) Biotechnology Co., Ltd* (華胤(深圳)生物科技有限公司) (“**Huayin Biotechnology**”), a company managed by StarGlory Shenzhen, Huayin Biotechnology officially launched a series of new skincare products (the “**Products**”) in the PRC on 22 December 2020 in relation to freckle removal and skin whitening under the brand name “NA+NP BEAUTY MARKING TIME NONERAPOSTO BEAUTY MARKING TIME”. The Products, which include facial cleanser, spray, serum, eye serum, cream and mask, are developed by Huayin Biotechnology using a biological DNA metabolism enzyme technology named “PH450” (“**PH450 Enzyme Technology**”). The Company was informed that Huayin Biotechnology acquired the exclusive right of PH450 Enzyme Technology in 2020 and obtained patent rights for the “Mass Preparation Method of PH450 Enzyme* (PH450酶的大量製備方法)” in the same year. The Company was also informed that, the inventor of the “Mass Preparation Method of PH450 Enzyme”, Arber Werner, is a Swiss biologist who won the 1978 Nobel Prize in Medicine and Physiology and is known as “the father of global cell enzymes”. As a leading life science technology around the world, the PH450 Enzyme Technology can directly dissolve and metabolize skin cytochromes, toxins and inflammation problems, promote cell circulation and discharge cell precipitation toxins, and improve cell survival by adding telomerase activation technology to achieve “Longevity Proteins (長壽蛋白)” regeneration, through which the mitochondrial organelles are renewed to activate cell energy and renew the skin. With the use of the PH450 Enzyme Technology, the Products are expected to discharge dark yellow pigment from the skin, adjust cell metabolism renewal, improve the dull and yellow skin, and restore the skin to health and vitality, whitening and renewing.

As per the statistics from “2020 China’s Anti-freckle Skin Care Products Market Prospects and Current Situation Analysis Report (2020年中國祛斑護膚品市場行業前景、現狀分析報告)”, approximately 98% of women in China are affected by different degrees of stains, and more than 85% of them are between 18 and 45 years old. Taking into account the increasing customer expectation and spending power of modern women in relation to beauty and skin maintenance, it is considered that the skincare products for freckle removal and skin whitening have huge market demand and growth potential. Accordingly, by taking females as the main target customers, the Board believes that the Products will be welcomed and well-recognized by the market and will become a competitive market player in the future.

The Board is of the view that the launch of the Products by Huayin Biotechnology can help the Group to expand in healthcare business, which is conducive to diversifying the Group’s revenue stream and improving its competitiveness so as to create a new growth driver for the Group’s business development.

By order of the Board
StarGlory Holdings Company Limited
Huang Chao
Chairman and executive Director

Hong Kong, 22 December 2020

As at the date of this announcement, the executive Directors are Mr. Huang Chao and Mr. Wu Xiaowen; and the independent non-executive Directors are Mr. Chan Yee Ping Michael, Mr. Yang Haiyu and Mr. Zeng Shiquan.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Listed Company Information” page for at least 7 days from the date of its posting and the website of the Company at www.stargloryhcl.com.

* *for identification purposes only*